Ultragenyx Pharmaceutical Inc.

The sponsor supports studies in Angelman syndrome and mucopolysaccharidosis type IIIA, with attention to cognitive function, neurological impairment, and long-term disease management in genetic conditions that affect development and the nervous system.

• Angelman syndrome
• Mucopolysaccharidosis type IIIA

These programs address both symptomatic impact and durable treatment effects in rare inherited disorders with central nervous system involvement.

Ultragenyx also funds clinical work in osteogenesis imperfecta, a rare skeletal disorder marked by bone fragility and recurrent fractures, with research centered on fracture reduction and improved skeletal outcomes.

• Osteogenesis imperfecta
• Brittle bone syndrome

This area highlights sustained interest in pediatric and lifelong management of inherited bone disease.

A substantial part of the sponsor’s clinical activity involves gene therapy and extended monitoring in rare diseases, including inherited metabolic, neurological, and skeletal disorders. The portfolio includes studies designed to assess lasting safety, tolerability, and disease control after treatment in diverse genetic conditions.

• Gene therapy
• Long-term safety
• Inherited rare disease care

Research activity spans multiple countries and collaborating sites, supporting clinical development across several distinct rare disease programs.